Literature DB >> 8504500

Shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator therapy.

W Grimm1, B T Flores, F E Marchlinski.   

Abstract

BACKGROUND: The purpose of this study was to determine the influence of clinical characteristics on shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator (ICD) therapy. METHODS AND
RESULTS: Two hundred forty-one consecutive patients underwent ICD implantation between November 1982 and November 1991 and were subsequently followed for 26 +/- 22 months (intention-to-treat analysis). Actuarial incidence of "appropriate" shocks was 13%, 42%, and 63%, and the incidence of any spontaneous shocks was 15%, 51%, and 76% at 1, 3, and 5 years of follow-up, respectively. Poor left ventricular function (ejection fraction < or = 30%) was associated with an earlier occurrence of both appropriate and any spontaneous ICD shocks (p = 0.001). Appropriate and any spontaneous shocks occurred significantly later in patients who presented with cardiac arrest and in patients in whom only ventricular fibrillation but no uniform ventricular tachycardia was induced during preoperative programmed stimulation. In addition, amiodarone treatment at implant was associated with later occurrence of any spontaneous shocks. Cumulative survival from all-cause mortality including perioperative mortality was 84%, 62%, and 57%, and survival from arrhythmic death was 97%, 89%, and 83% at 1, 3, and 5 years, respectively. Ejection fraction < or = 30% was the best predictor of both total arrhythmic death (p = 0.019) and total mortality (p = 0.003). Antiarrhythmic therapy with class 1 agents at implant was also associated with a higher total mortality during follow-up (p = 0.023) but not with total arrhythmic death. Age, sex, underlying heart disease, clinical presentation, and preoperative response to programmed stimulation did not predict long-term survival. In addition, survival curves were similar for patients with and without spontaneous shocks.
CONCLUSIONS: The majority of patients receive shocks during long-term follow-up. The occurrence of appropriate or any spontaneous shocks during follow-up is not associated with increased arrhythmic or total mortality consistent with effective prevention of sudden cardiac death with ICD therapy in this high-risk patient population. Although low ejection fraction is the strongest predictor of both shock occurrence and mortality during follow-up, no easy algorithm can be derived from the analyzed clinical characteristics to predict which patients will benefit most from ICD implantation.

Entities:  

Mesh:

Year:  1993        PMID: 8504500     DOI: 10.1161/01.cir.87.6.1880

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies.

Authors:  A Verma; F Kilicaslan; D O Martin; S Minor; R Starling; N F Marrouche; S Almahammed; O M Wazni; S Duggal; R Zuzek; H Yamaji; J Cummings; M K Chung; P J Tchou; A Natale
Journal:  Heart       Date:  2005-05-27       Impact factor: 5.994

2.  Prognostic impact of recurrences of ventricular tachyarrhythmias and appropriate ICD therapies in a high-risk ICD population.

Authors:  Tobias Schupp; Ibrahim Akin; Linda Reiser; Armin Bollow; Gabriel Taton; Thomas Reichelt; Dominik Ellguth; Niko Engelke; Uzair Ansari; Kambis Mashayekhi; Christel Weiß; Christoph Nienaber; Muharrem Akin; Martin Borggrefe; Michael Behnes
Journal:  Clin Res Cardiol       Date:  2019-02-12       Impact factor: 5.460

3.  Increased Platelet-to-Lymphocyte Ratios and Low Relative Lymphocyte Counts Predict Appropriate Shocks in Heart Failure Patients with ICDs.

Authors:  Kevser Gülcihan Balci; Mustafa Mücahit Balci; Ugur Arslan; Burak Açar; Orhan Maden; Hatice Selcuk; Timur Selcuk
Journal:  Acta Cardiol Sin       Date:  2016-09       Impact factor: 2.672

4.  Quality of life predicts one-year survival in patients with implantable cardioverter defibrillators.

Authors:  Chi-Wen Kao; Erika Friedmann; Sue A Thomas
Journal:  Qual Life Res       Date:  2010-02-03       Impact factor: 4.147

5.  Impact of advanced age on survival in patients with implantable cardioverter defibrillators.

Authors:  Cara N Pellegrini; Keane Lee; Jeffrey E Olgin; Mintu P Turakhia; Zian H Tseng; Randall Lee; Nitish Badhwar; Byron Lee; Paul D Varosy
Journal:  Europace       Date:  2008-09-24       Impact factor: 5.214

6.  2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.

Authors:  Bruce L Wilkoff; Laurent Fauchier; Martin K Stiles; Carlos A Morillo; Sana M Al-Khatib; Jesœs Almendral; Luis Aguinaga; Ronald D Berger; Alejandro Cuesta; James P Daubert; Sergio Dubner; Kenneth A Ellenbogen; N A Mark Estes; Guilherme Fenelon; Fermin C Garcia; Maurizio Gasparini; David E Haines; Jeff S Healey; Jodie L Hurtwitz; Roberto Keegan; Christof Kolb; Karl-Heinz Kuck; Germanas Marinskis; Martino Martinelli; Mark McGuire; Luis G Molina; Ken Okumura; Alessandro Proclemer; Andrea M Russo; Jagmeet P Singh; Charles D Swerdlow; Wee Siong Teo; William Uribe; Sami Viskin; Chun-Chieh Wang; Shu Zhang
Journal:  J Arrhythm       Date:  2016-02-01

Review 7.  Potential risks of iatrogenic complications of nerve conduction studies (NCS) and electromyography (EMG).

Authors:  A Gechev; N M Kane; M Koltzenburg; D G Rao; R van der Star
Journal:  Clin Neurophysiol Pract       Date:  2016-10-13

8.  Inappropriate Shock delivered by Implantable Cardioverter Defibrillator--Cardiac Resynchronization Therapy (ICD-CRT) due to myopotential oversensing.

Authors:  Hamid Barakpour; Zahra Emkanjoo; Abolfath Alizadeh; Mohammad Ali Sadr-Ameli
Journal:  Indian Pacing Electrophysiol J       Date:  2009-01-07

9.  Risk of death and recurrent ventricular arrhythmias in survivors of cardiac arrest concurrent with acute myocardial infarction.

Authors:  Ish Singla; Haitham Hreybe; Samir Saba
Journal:  Indian Pacing Electrophysiol J       Date:  2008-02-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.